Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

Future Oncol. 2016 Dec;12(23):2689-2699. doi: 10.2217/fon-2016-0298. Epub 2016 Aug 16.

Abstract

Aim: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC).

Patients & methods: Treatment Registry for Outcomes in CRPC Patients (TRUMPET) is a US-based, prospective, observational multicenter registry (NCT02380274) involving patients with CRPC and their caregivers. Patients initiating their first active treatment course will be enrolled from urology and medical oncology practices, with data captured up to 4 years.

Results: Information on prescribing patterns, HRQoL, clinical outcomes and healthcare utilization will be collected.

Conclusion: TRUMPET will enable scientific understanding of disease management in terms of HRQoL, clinical outcomes and healthcare utilization in clinical practice for patients with CRPC.

Keywords: castration-resistant prostate cancer; health-related quality of life; treatment utilization.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Caregivers
  • Disease Management
  • Health Care Costs
  • Health Care Surveys
  • Humans
  • Male
  • Patient Acceptance of Health Care
  • Patient Satisfaction
  • Prostatic Neoplasms, Castration-Resistant / diagnosis
  • Prostatic Neoplasms, Castration-Resistant / epidemiology*
  • Prostatic Neoplasms, Castration-Resistant / therapy
  • Quality of Life
  • Quality-Adjusted Life Years
  • Registries
  • Research
  • Treatment Outcome
  • United States / epidemiology